Saved in:
| Main Authors: | , |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Subjects: | |
| Online Access: | https://doi.org/10.5281/zenodo.19922882 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p class="MsoNormal"><strong><span>Abstract</span></strong></p> <p class="MsoNormal"><span>Four new pyrazolo[3,4-d]pyrimidines (4)–(7) were successfully synthesized in good yields by reacting 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol with various alkylating agents (methyl iodide, tert-benzyl bromide, benzyl chloride,) at room temperature in DMF using liquid-solid phase transfer catalysis. The structures of (4)–(7) were proven by NMR spectroscopy. The anticancer activities of (4)–(7) against human colorectal carcinoma (HCT 116), human hepatocellular carcinoma (HepG2), and human breast cancer (MCF-7) cell lines, as well as one normal cell line (WI38) were investigated using MTT assay and sunitinib as a reference. Compounds (4) and (5) exhibited anticancer activity comparable to the reference drug against all tested cells, with an IC50 range of 22.7–40.75 μM. Both compounds also demonstrated high selectivity indices and minimal cytotoxic effects on normal cell lines.</span></p> <p class="MsoNormal"> </p>